Immunohistochemistry and Cancer Diagnosis
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 February 2018) | Viewed by 51459
Special Issue Editor
Interests: predictive biomarkers in lung cancer; liquid biopsy; molecular biology; artificial intelligence
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunohistochemistry is a pivotal tool allowing to quickly perform the diagnosis of many cancers, but also to establish the prognosis of some of them. More recently, IHC, through the use of new biomarkers, can be predictive of responsiveness of some targeted therapies. In this latter field, a couple of antibodies have been developed and can be routinely used to predict the efficiency of drugs targeting some genomic alterations; not only some mutations, but also some rearrangements. More recently, different antibodies have been available to be predictive of immunotherapy, in particular some PD-L1 antibodies which can be used as a companion or as a complementary diagnostic test for PD1/PDL1 molecules. Many other antibodies will come soon in the future to detect other molecules which could be predictive of new other immunotherapies. However, it is crucial to look for high quality development/control when using antibodies dedicated to theranosis. Currently, the route for laboratory developed test and commercial test is very challenging and complex, particularly to ensure that cancer patients can receive the accurate and representative test outcomes. In this context, accreditation process is certainly one of the best practices to be set up in pathology laboratories to ensure the quality of IHC results.
This Special Issue will highlight the current development of IHC in cancer: it will provide, i) a practical approach in the interpretation and immunohistochemical selection of lung/pleura-based neoplasms obtained from small biopsy and cytological samples, ii) the use of new predictive biomarkers which can provide results essential for timely and accurate therapeutic decision making in the era of the so called stratified medicine, iii) some algorithms using IHC for improvement of CUP diagnosis, and iv) the interest to get accreditation in IHC for a pathology laboratory to ensure a high quality level of the results.
Prof. Dr. Paul HofmanGuest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
